Assuming the COMPASS results are enough to convince regulators to make the low dose of rivaroxaban used in the study available to clinicians, the trial should influence how patients with stable ...
The final prototype, in the shape of a magnifying glass, stands tall in a 10th-floor conference room at real estate startup Compass, emitting a gentle glow from the inner rim of its ringed frame. At ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results